Addex Therapeutics (NASDAQ:ADXN) Shares Down 0.7% – What’s Next?

Addex Therapeutics Ltd (NASDAQ:ADXN) was down 0.7% during mid-day trading on Tuesday . The stock traded as low as $8.50 and last traded at $8.07. Approximately 674 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 92,720 shares. The stock had previously closed at $8.12.

Addex Therapeutics Price Performance

The company has a market capitalization of $8.55 million, a P/E ratio of -23.72 and a beta of 1.62. The company has a 50 day moving average of $7.56 and a 200-day moving average of $7.88.

Institutional Trading of Addex Therapeutics

A hedge fund recently bought a new stake in Addex Therapeutics stock. Citadel Advisors LLC bought a new position in Addex Therapeutics Ltd (NASDAQ:ADXN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,079 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 1.14% of Addex Therapeutics at the end of the most recent reporting period. Institutional investors own 16.14% of the company’s stock.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.